Cel Sci (CVM) Shares Outstanding (2010 - 2026)
Cel Sci (CVM) posted Shares Outstanding (Entity) of $1.0 million for Q1 2026, down 7.4% sequentially from $1.1 million in Q4 2025, and up 72.42% YoY from $598960.0 in Q1 2025.
Cel Sci (CVM) Shares Outstanding (2010 - 2026) Analysis & Trends
Cel Sci has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 72.42% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 72.42% YoY) and the FY2025 annual result came in at $749786.0, up 28.56% from the prior year.
- Shares Outstanding (Entity) retreated to $1.0 million in Q1 2026 per CVM's latest filing, from $1.1 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $1.8 million in Q2 2024 and troughed at $583202.0 in Q3 2024.
- A 5-year average of $1.2 million and a median of $1.4 million in 2022 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 76.28% in 2025, down 67.48% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $1.5 million in 2022, then grew by 14.39% to $1.7 million in 2023, then sank by 62.05% to $632651.0 in 2024, then jumped by 76.28% to $1.1 million in 2025, then declined by 7.4% to $1.0 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.0 million, $1.1 million, and $749786.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 445.06 Mn |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | 1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 749,786.00 |
| Jun 30, 2025 | 588,121.00 |
| Mar 31, 2025 | 598,960.00 |
| Dec 31, 2024 | 632,651.00 |
| Sep 30, 2024 | 583,202.00 |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.62 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 1.45 Mn |
| Dec 31, 2022 | 1.45 Mn |
| Sep 30, 2022 | 1.44 Mn |
| Jun 30, 2022 | 1.44 Mn |
| Mar 31, 2022 | 1.44 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Sep 30, 2021 | 1.36 Mn |
| Jun 30, 2021 | 1.37 Mn |